Vaccination of cancer patients with tumor-specific antigens, and biology of cytokines

Informazioni relative al progetto

TUMOR VACCINES, CYTO

ID dell’accordo di sovvenzione: QLG1-CT-2000-60013

Progetto chiuso

Data di avvio 21 Gennaio 2002

Data di completamento 20 Gennaio 2006

Finanziato da

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Costo totale € 480 000,00

Contributo UE € 480 000,00

Coordinato da

CHRISTIAN DE DUVE INSTITUTE OF CELLULAR PATHOLOGY
Belgium

Obiettivo

Our groups work on the characterization of human tumour-specific antigens recognized by T lymphocytes, the use of these antigens for therapeutic vaccination of cancer patients, and the biology of new cytokines.

Campo scientifico

• medical and health sciences › clinical medicine › oncology

Programma(i)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Argomento(i)

• 1.1.1.-7. - Chronic and degenerative diseases, cancer, diabetes, cardivascular diseases and rare diseases

Invito a presentare proposte

Data not available

Meccanismo di finanziamento

BUR - Bursaries, grants, fellowships

Coordinatore

CHRISTIAN DE DUVE INSTITUTE OF CELLULAR PATHOLOGY

• Contributo UE: Nessun dato
• Indirizzo: Avenue Hippocrate 74 ; 1200 BRUXELLES ; Belgio
• Costo totale: Nessun dato